{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc.balversa:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc.balversa%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00469,
    "timestamp_received": "2026-04-06T14:50:53.445525+00:00Z",
    "timestamp_returned": "2026-04-06T14:50:53.450215+00:00Z",
    "trace_id": "85822145-5046-473d-8bbe-30ff5fd5e354"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-03-05"
  },
  "data": [
    {
      "id": "ind:hc.balversa:0",
      "indication": "BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",
      "initial_approval_date": null,
      "initial_approval_url": null,
      "description": "Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",
      "raw_biomarkers": "susceptible FGFR3 genetic alterations",
      "raw_cancer_type": "locally advanced unresectable or metastatic urothelial carcinoman (UC)",
      "raw_therapeutics": "Balversa (erdafitinib)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hc.balversa",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Balversa (erdafitinib) [product monograph]. HC.",
        "title": null,
        "aliases": [],
        "description": "Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.",
        "urls": [
          "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320",
          "https://pdf.hres.ca/dpd_pm/00077812.PDF"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hc",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Canada",
              "description": "Regulatory agency that approves drugs for sale and use in Canada.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-06-11",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://health-products.canada.ca/dpd-bdpp/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Janssen Inc.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Balversa",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "erdafitinib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2019-10-25",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-11-20",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}